- GlobeNewswire•12 days ago
Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies
CARMIEL, Israel, April 18, 2017-- Protalix BioTherapeutics, Inc., announced today new, promising results from a preclinical trial conducted in collaboration with Prof. Raphael Schiffmann, Director, Institute ...
- Accesswire•17 days ago
NEW YORK, NY / ACCESSWIRE / April 13, 2017 / These two companies are finding the FDA trial process to be less predictable than anticipated. Apricus has investors optimistic, while Protalix is putting its ...
- TheStreet.com•18 days ago
The Protalix medicine alidornase alfa is designed to help cystic fibrosis patients clear their lungs by making mucus thin and loose.
PLX : Summary for Protalix BioTherapeutics, Inc. - Yahoo Finance
Protalix BioTherapeutics, Inc. (PLX)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Bid||0.92 x 13800|
|Ask||0.93 x 12500|
|Day's Range||0.90 - 1.00|
|52 Week Range||0.26 - 1.51|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.21|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|